title: Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene.
abstract: Gene transfer of the Escherichia coli purine nucleoside phosphorylase (PNP) results in potent cytotoxicity after administration of the prodrug fludarabine phosphate (F-araAMP). Here, we have tested whether application of this strategy in the context of replication-competent retrovirus (RCR) vectors, which can achieve highly efficient tumor-restricted transduction as well as persistent expression of transgenes, would result in effective tumor inhibition, or, alternatively, would adversely affect viral replication. We found that RCR vectors could achieve high levels of PNP expression concomitant with the efficiency of their replicative spread, with significant cell killing activity in vitro and potent therapeutic effects in vivo. In U-87 xenograft models, replicative spread of the vector resulted in progressive transmission of the PNP transgene, as evidenced by increasing PNP enzyme activity with time after vector inoculation. On F-araAMP administration, high efficiency gene transfer of PNP by the RCR vector resulted in significant suppression of tumor growth and extended survival time. As the RCR mediates stable integration of the PNP gene and continuous expression, an additional round of F-araAMP administration resulted in further survival benefit. RCR-mediated PNP suicide gene therapy thus represents a highly efficient form of intracellular chemotherapy, and may achieve effective antitumor activity with less systemic toxicity.
authors.affiliation: Department of Life Science, National Chung Cheng University, Min-Hsiung, Chia-Yi, Taiwan.
authors.forename: C-K
authors.initials: CK
authors.lastname: Tai
authors.forename: W
authors.initials: W
authors.lastname: Wang
authors.forename: Y-H
authors.initials: YH
authors.lastname: Lai
authors.forename: C R
authors.initials: CR
authors.lastname: Logg
authors.forename: W B
authors.initials: WB
authors.lastname: Parker
authors.forename: Y-F
authors.initials: YF
authors.lastname: Li
authors.forename: J S
authors.initials: JS
authors.lastname: Hong
authors.forename: E J
authors.initials: EJ
authors.lastname: Sorscher
authors.forename: T C
authors.initials: TC
authors.lastname: Chen
authors.forename: N
authors.initials: N
authors.lastname: Kasahara
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D004926:Escherichia coli / Q000201:enzymology*; D015316:Genetic Therapy; D005822:Genetic Vectors; D005910:Glioma / Q000235:genetics / Q000628:therapy* / Q000821:virology; D049452:Green Fluorescent Proteins / Q000378:metabolism; D006801:Humans; D015552:Injections, Intralesional; D007279:Injections, Subcutaneous; D051379:Mice; D008819:Mice, Nude; D011355:Prodrugs / Q000494:pharmacology*; D011683:Purine-Nucleoside Phosphorylase / Q000235:genetics*; D012190:Retroviridae / Q000235:genetics*; D001084:Vidarabine Phosphate / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D000964:Antimetabolites, Antineoplastic; D011355:Prodrugs; C485184:enhanced green fluorescent protein; D001084:Vidarabine Phosphate; D049452:Green Fluorescent Proteins; C042382:fludarabine phosphate; D011683:Purine-Nucleoside Phosphorylase
references.citation: Cancer Res. 2004 Sep 15;64(18):6610-5
references.pmid: 15374975
references.citation: Mol Cell Biol. 1987 Jan;7(1):379-87
references.pmid: 3031469
references.citation: Hepatology. 2000 Mar;31(3):606-14
references.pmid: 10706550
references.citation: Cancer Gene Ther. 1997 Mar-Apr;4(2):118-28
references.pmid: 9080121
references.citation: J Pharmacol Exp Ther. 2003 Mar;304(3):1280-4
references.pmid: 12604707
references.citation: J Gene Med. 2004 Jan;6(1):43-54
references.pmid: 14716676
references.citation: Hum Gene Ther. 1990 Spring;1(1):15-30
references.pmid: 1964393
references.citation: Hum Gene Ther. 2001 May 20;12(8):921-32
references.pmid: 11387057
references.citation: Clin Cancer Res. 2006 Dec 1;12(23):7108-16
references.pmid: 17145835
references.citation: Hum Gene Ther. 2000 Nov 20;11(17):2389-401
references.pmid: 11096443
references.citation: Hum Gene Ther. 2003 Jan 20;14(2):117-27
references.pmid: 12614563
references.citation: Mol Ther. 2005 Nov;12(5):842-51
references.pmid: 16257382
references.citation: Hum Gene Ther. 1991 Fall;2(3):215-9
references.pmid: 1661171
references.citation: Science. 2003 Oct 17;302(5644):415-9
references.pmid: 14564000
references.citation: Hum Gene Ther. 1997 Sep 20;8(14):1637-44
references.pmid: 9322865
references.citation: Gene Ther. 2002 Jun;9(12):759-68
references.pmid: 12040457
references.citation: Biochem Pharmacol. 1998 May 15;55(10):1673-81
references.pmid: 9634004
references.citation: Neurosurg Focus. 2006 Apr 15;20(4):E25
references.pmid: 16709031
references.citation: Gene Ther. 2004 Nov;11(21):1559-67
references.pmid: 15343359
references.citation: Acta Pathol Microbiol Scand. 1968;74(4):465-86
references.pmid: 4313504
references.citation: Cancer Gene Ther. 2007 Mar;14(3):279-86
references.pmid: 17218950
references.citation: Cancer Gene Ther. 2002 Dec;9(12):1022-35
references.pmid: 12522441
references.citation: Cancer Res. 2007 Jun 1;67(11):5345-53
references.pmid: 17545615
references.citation: Gene Ther. 2000 Oct;7(20):1738-43
references.pmid: 11083495
references.citation: J Virol. 1990 Dec;64(12):6176-83
references.pmid: 1700832
references.citation: Science. 2002 Oct 4;298(5591):34-5
references.pmid: 12364755
references.citation: J Exp Med. 1992 Oct 1;176(4):1125-35
references.pmid: 1383375
references.citation: J Gene Med. 2004 Dec;6(12):1343-57
references.pmid: 15493036
references.citation: Hum Gene Ther. 1999 Mar 1;10(4):649-57
references.pmid: 10094208
references.citation: J Virol. 2002 Dec;76(24):12783-91
references.pmid: 12438603
references.citation: Nat Med. 2001 Jul;7(7):781-7
references.pmid: 11433341
references.citation: Science. 2002 Apr 19;296(5567):497
references.pmid: 11964471
references.citation: Gene Ther. 1994 Jul;1(4):233-8
references.pmid: 7584086
references.citation: Cancer Gene Ther. 2003 Jan;10(1):23-9
references.pmid: 12489025
references.citation: Hum Gene Ther. 2003 May 20;14(8):789-802
references.pmid: 12804141